PURPOSE: Tamoxifen remains therapy of choice for premenopausal estrogen receptor alpha-positive breast cancer. However, resistance and recurrence are serious problems. Our previous work indicated that carcinoembryonic antigen cell adhesion molecule 6 (CEACAM6) was significantly up-regulated in tamoxifen-resistant (TAMr) MCF-7 derivatives. The aim of this study was to determine the functional role of CEACAM6 in endocrine-resistant breast cancer and to retrospectively test whether it was predictive of resistance in a large cohort of breast cancers with long-term follow-up. EXPERIMENTAL DESIGN: siRNA silencing of CEACAM6 was done in TAMr cells and effects on clonogenicity and endocrine sensitivity were determined. CEACAM6 immunohistochemistry was done on a tissue microarray comprising 108 relapsed primary human breast cancers and 243 tamoxifen-sensitive controls. RESULTS: siRNA-mediated silencing of CEACAM6 reduced both clonogenicity and anchorage-dependent and anchorage-independent growth of TAMr cells. Importantly, CEACAM6 silencing restored sensitivity of TAMr cells to 4-hydroxytamoxifen and proliferative response to 17beta-estradiol. Immunohistochemistry showed significantly more CEACAM expression in the relapsed group compared with nonrelapsed controls [35 of 108 (33.3%) and 32 of 243 (13.2%), respectively; odds ratio, 3.16 (95% confidence interval, 1.83-5.47); P < 0.0001]. Additionally, we derived an outcome predictor model based on CEACAM expression that restratified patients in the Nottingham prognostic index intermediate-risk group into either higher-risk or lower-risk group. CONCLUSIONS: Our data support an important role for CEACAM6 in endocrine resistance, which can serve as a powerful predictor of future recurrence.
PURPOSE:Tamoxifen remains therapy of choice for premenopausal estrogen receptor alpha-positive breast cancer. However, resistance and recurrence are serious problems. Our previous work indicated that carcinoembryonic antigen cell adhesion molecule 6 (CEACAM6) was significantly up-regulated in tamoxifen-resistant (TAMr) MCF-7 derivatives. The aim of this study was to determine the functional role of CEACAM6 in endocrine-resistant breast cancer and to retrospectively test whether it was predictive of resistance in a large cohort of breast cancers with long-term follow-up. EXPERIMENTAL DESIGN: siRNA silencing of CEACAM6 was done in TAMr cells and effects on clonogenicity and endocrine sensitivity were determined. CEACAM6 immunohistochemistry was done on a tissue microarray comprising 108 relapsed primary humanbreast cancers and 243 tamoxifen-sensitive controls. RESULTS: siRNA-mediated silencing of CEACAM6 reduced both clonogenicity and anchorage-dependent and anchorage-independent growth of TAMr cells. Importantly, CEACAM6 silencing restored sensitivity of TAMr cells to 4-hydroxytamoxifen and proliferative response to 17beta-estradiol. Immunohistochemistry showed significantly more CEACAM expression in the relapsed group compared with nonrelapsed controls [35 of 108 (33.3%) and 32 of 243 (13.2%), respectively; odds ratio, 3.16 (95% confidence interval, 1.83-5.47); P < 0.0001]. Additionally, we derived an outcome predictor model based on CEACAM expression that restratified patients in the Nottingham prognostic index intermediate-risk group into either higher-risk or lower-risk group. CONCLUSIONS: Our data support an important role for CEACAM6 in endocrine resistance, which can serve as a powerful predictor of future recurrence.
Authors: Hakeemah Al-Nakhle; Philip A Burns; Michele Cummings; Andrew M Hanby; Thomas A Hughes; Sampoorna Satheesha; Abeer M Shaaban; Laura Smith; Valerie Speirs Journal: Cancer Res Date: 2010-05-18 Impact factor: 12.701
Authors: Werbena Hamilton-Burke; Louise Coleman; Michele Cummings; Caroline A Green; Deborah L Holliday; Kieran Horgan; Loaie Maraqa; Mark B Peter; Steven Pollock; Abeer M Shaaban; Laura Smith; Valerie Speirs Journal: Am J Pathol Date: 2010-08-09 Impact factor: 4.307
Authors: Shanaz H Dairkee; Aejaz Sayeed; Gloria Luciani; Stacey Champion; Zhenhang Meng; Lakshmi R Jakkula; Heidi S Feiler; Joe W Gray; Dan H Moore Journal: Cancer Res Date: 2009-09-29 Impact factor: 12.701
Authors: Joan S Lewis-Wambi; Heather E Cunliffe; Helen R Kim; Amanda L Willis; V Craig Jordan Journal: Eur J Cancer Date: 2008-07-07 Impact factor: 9.162
Authors: L J Coleman; M B Peter; T J Teall; R A Brannan; A M Hanby; H Honarpisheh; A M Shaaban; L Smith; V Speirs; E T Verghese; J N McElwaine; T A Hughes Journal: Br J Cancer Date: 2009-04-14 Impact factor: 7.640
Authors: M Kobayashi; Y Miki; M Ebina; K Abe; K Mori; S Narumi; T Suzuki; I Sato; M Maemondo; C Endo; A Inoue; H Kumamoto; T Kondo; H Yamada-Okabe; T Nukiwa; H Sasano Journal: Br J Cancer Date: 2012-10-25 Impact factor: 7.640